

Debulking Surgery or Biopsy
Randomization with Stratification
Based on RPA Class and Region
(N=460)
(N=460)
RT 2 Gy 5 Days/Wk for 6 Wks
TMZ 75 mg/m2/qd
Placebo 10 mg/kg q2w
RT 2 Gy 5 Days/Wk for 6 Wks
TMZ 75 mg/m2/qd
Bevacizumab 10 mg/kg q2w
Treatment Break 4 wks
TMZ 150 -200 mg/m2/qd d1-d5 q28d
Placebo 10 mg/kg q2w
TMZ 150 -200 mg/m2/qd d1-d5 q28d
Bevacizumab 10 mg/kg q2w
Placebo
15 mg/kg q3w
Monotherapy
Until Disease Progression
Bevacizumab
15 mg/kg q3w
Monotherapy
Until Disease Progression
Treatment Start Between 28 to 49 Days Post Surgery
Concurrent Phase
Maintenance Phase For 6 Cycles
Monotherapy Phase Until PD

FIG. 1



Progression Free Survival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
3
6
9
12
15
18
21
24
27
30
33
36
Study Month
n at Risk
Pl+RT/T 463 349 247 170 110 77 47 23 8 4 0 0 0
Bv+RT/T 458 424 366 278 189 104 71 25 13 2 1 0 0
Randomized Treatment
Pl+RT/T
Bv+RT/T

FIG. 2